KEAP1 Protein

Migration, Crosslink

📖

KEAP1 Protein

active

wiki page Created: 2026-04-02T07:19:11 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-proteins-keap1-protein

📖 Wiki Page

protein2974 wordssynced 2026-04-02

KEAP1 Protein

<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">KEAP1 Protein</th>
</tr>
<tr>
<td class="label">Gene/Protein</td>
<td>Function</td>
</tr>
<tr>
<td class="label">[NQO1](/genes/nqo1)</td>
<td>NAD(P)H quinone dehydrogenase 1 - detoxification</td>
</tr>
<tr>
<td class="label">[HO-1](/genes/hmox1)</td>
<td>Heme oxygenase-1 - antioxidant, anti-inflammatory</td>
</tr>
<tr>
<td class="label">[GCLC](/genes/gclc)</td>
<td>Glutamate-cysteine ligase catalytic subunit - GSH synthesis</td>
</tr>
<tr>
<td class="label">[GCLM](/genes/gclm)</td>
<td>Glutamate-cysteine ligase modifier subunit</td>
</tr>
<tr>
<td class="label">[TXNRD1](/genes/txnrd1)</td>
<td>Thioredoxin reductase 1 - redox balance</td>
</tr>
<tr>
<td class="label">[SOD1](/genes/sod1)</td>
<td>Superoxide dismutase 1 - ROS scavenging</td>
</tr>
<tr>
<td class="label">[CAT](/genes/cat)</td>
<td>Catalase - hydrogen peroxide detoxification</td>
</tr>
<tr>
<td class="label">[GSTA1](/genes/gsta1)</td>
<td>Glutathione S-transferase A1 - detoxification</td>
</tr>
<tr>
<td class="label">[PRDX1](/genes/prdx1)</td>
<td>Peroxiredoxin 1 - peroxynitrite detoxification</td>
</tr>
<tr>
<td class="label">Disease</td>
<td>KEAP1-Nrf2 Status</td>
</tr>
<tr>
<td class="label">Amyotrophic Lateral Sclerosis (ALS)</td>
<td>Reduced Nrf2 activity in motor neurons; KEAP1 mutations identified in some familial cases[@inoue2019]</td>
</tr>
<tr>
<td

...

KEAP1 Protein

<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">KEAP1 Protein</th>
</tr>
<tr>
<td class="label">Gene/Protein</td>
<td>Function</td>
</tr>
<tr>
<td class="label">[NQO1](/genes/nqo1)</td>
<td>NAD(P)H quinone dehydrogenase 1 - detoxification</td>
</tr>
<tr>
<td class="label">[HO-1](/genes/hmox1)</td>
<td>Heme oxygenase-1 - antioxidant, anti-inflammatory</td>
</tr>
<tr>
<td class="label">[GCLC](/genes/gclc)</td>
<td>Glutamate-cysteine ligase catalytic subunit - GSH synthesis</td>
</tr>
<tr>
<td class="label">[GCLM](/genes/gclm)</td>
<td>Glutamate-cysteine ligase modifier subunit</td>
</tr>
<tr>
<td class="label">[TXNRD1](/genes/txnrd1)</td>
<td>Thioredoxin reductase 1 - redox balance</td>
</tr>
<tr>
<td class="label">[SOD1](/genes/sod1)</td>
<td>Superoxide dismutase 1 - ROS scavenging</td>
</tr>
<tr>
<td class="label">[CAT](/genes/cat)</td>
<td>Catalase - hydrogen peroxide detoxification</td>
</tr>
<tr>
<td class="label">[GSTA1](/genes/gsta1)</td>
<td>Glutathione S-transferase A1 - detoxification</td>
</tr>
<tr>
<td class="label">[PRDX1](/genes/prdx1)</td>
<td>Peroxiredoxin 1 - peroxynitrite detoxification</td>
</tr>
<tr>
<td class="label">Disease</td>
<td>KEAP1-Nrf2 Status</td>
</tr>
<tr>
<td class="label">Amyotrophic Lateral Sclerosis (ALS)</td>
<td>Reduced Nrf2 activity in motor neurons; KEAP1 mutations identified in some familial cases[@inoue2019]</td>
</tr>
<tr>
<td class="label">Huntington's Disease</td>
<td>Nrf2 pathway activation is protective in HD models</td>
</tr>
<tr>
<td class="label">Multiple Sclerosis</td>
<td>Nrf2 activation reduces neuroinflammation in preclinical models[@cuadrado2019]</td>
</tr>
<tr>
<td class="label">Frontotemporal Dementia</td>
<td>Dysregulated Nrf2 signaling reported</td>
</tr>
<tr>
<td class="label">Prion Disease</td>
<td>Impaired Nrf2 activation contributes to oxidative damage</td>
</tr>
<tr>
<td class="label">Vascular Dementia</td>
<td>Nrf2 activation improves cognitive function in models[@sundaram2024]</td>
</tr>
<tr>
<td class="label">Compound</td>
<td>Condition</td>
</tr>
<tr>
<td class="label">Dimethyl fumarate</td>
<td>Parkinson's Disease</td>
</tr>
<tr>
<td class="label">Sulforaphane</td>
<td>Alzheimer's Disease</td>
</tr>
<tr>
<td class="label">Bardoxolone methyl</td>
<td>Alzheimer's Disease</td>
</tr>
<tr>
<td class="label">SAK3 (a novel Nrf2 activator)</td>
<td>Alzheimer's Disease</td>
</tr>
<tr>
<td class="label">Protein</td>
<td>Interaction with KEAP1-Nrf2</td>
</tr>
<tr>
<td class="label">[PINK1](/genes/pink1)</td>
<td>Mitophagy regulation intersects with Nrf2 signaling</td>
</tr>
<tr>
<td class="label">[Parkin](/genes/parkin)</td>
<td>Ubiquitin-proteasome system dysfunction affects pathway</td>
</tr>
<tr>
<td class="label">[LRRK2](/genes/lrrk2)</td>
<td>Kinase activity modulates Nrf2 activation</td>
</tr>
<tr>
<td class="label">[SNCA](/genes/snca)</td>
<td>Aggregation sequesters Nrf2, impairs nuclear translocation</td>
</tr>
<tr>
<td class="label">[TREM2](/genes/trem2)</td>
<td>Microglial Nrf2 affects TREM2 expression and function</td>
</tr>
<tr>
<td class="label">[APOE](/genes/apoe)</td>
<td>Lipid metabolism links to oxidative stress response</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/als" style="color:#ef9a9a">ALS</a>, <a href="/wiki/alzheimer" style="color:#ef9a9a">ALZHEIMER</a>, <a href="/wiki/alzheimer's-disease" style="color:#ef9a9a">ALZHEIMER'S DISEASE</a>, <a href="/wiki/aging" style="color:#ef9a9a">Aging</a>, <a href="/wiki/als" style="color:#ef9a9a">Als</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">792 edges</a></td>
</tr>
</table>

Gene: [KEAP1](/genes/keap1) | Protein: KEAP1 (Kelch-like ECH-associated protein 1) | Aliases: INH5, KLHL19

Introduction

KEAP1 (Kelch-like ECH-associated protein 1) is a cysteine-rich adaptor protein that serves as the primary regulator of the [Nrf2](/proteins/nrf2-protein) transcription factor. First identified in 1999, KEAP1 acts as a molecular sensor for oxidative stress, forming a ubiquitin ligase complex that targets Nrf2 for degradation under basal conditions. When cells experience oxidative stress, specific cysteine residues on KEAP1 are modified, leading to Nrf2 stabilization, nuclear translocation, and activation of the antioxidant response element (ARE) genes.

The KEAP1-Nrf2 pathway is one of the most important cellular defense mechanisms against oxidative stress, and its dysfunction is strongly implicated in the pathogenesis of neurodegenerative diseases including [Alzheimer's disease](/diseases/alzheimers-disease) and [Parkinson's disease](/diseases/parkinsons-disease).

Structure and Biochemistry

Domain Architecture

KEAP1 is a 624-amino acid protein composed of several functional domains:

N-terminal region (NTR): Contains the intervening region (IVR) that mediates interaction with the Cullin 3 ubiquitin ligase complex

Broad complex, Tramtrack, and Bric-a-bract (BTB) domain: Mediates homodimerization and recruitment of Cullin 3

Double glycine repeat (DGR) or Kelch domain: The C-terminal kelch repeats form a six-bladed β-propeller structure that binds Nrf2

C-terminal region (CTR): Stabilizes the kelch domain structure

Cysteine Sensors

KEAP1 contains 27 cysteine residues, of which several serve as sensors for electrophiles and oxidative stress:

C151 (BTB domain): Primary sensor for electrophilic compounds, critical for Nrf2 activation
C273 and C288 (IVR): Important for oxidative stress sensing
C513 and C518 (Kelch domain): Contribute to Nrf2 binding affinity

The modification of these cysteine residues leads to conformational changes that prevent Nrf2 ubiquitination.

Three-Dimensional Structure

The crystal structure of KEAP1 has revealed critical insights into its mechanism:

The BTB domain forms a homodimer, with each monomer capable of binding one Nrf2 molecule
The kelch domain presents a negatively charged binding groove that interacts with the Nrf2 Neh2 domain
The spatial arrangement of cysteine residues suggests a coordinated oxidation sensing mechanism
The IVR domain acts as a flexible linker that undergoes conformational changes upon oxidation

Protein-Protein Interactions

The KEAP1 protein serves as a molecular hub, engaging in multiple protein-protein interactions essential for its function:

Nrf2 Binding (Neh2 Domain): The N-terminal Neh2 domain of Nrf2 contains two motifs that interact with KEAP1:

The ETGE motif (positions 79-82): High-affinity binding site
The DLG motif (positions 17-22): Low-affinity binding site required for ubiquitination

Cullin 3 Interaction: The BTB domain of KEAP1 directly binds to Cullin 3, forming the substrate recognition component of the CRL3 ubiquitin ligase complex.

RING Box Protein RBX1: Through its interaction with Cullin 3, KEAP1 recruits RBX1, which catalyzes ubiquitin transfer to Nrf2.

The KEAP1-Nrf2 Signaling Pathway

Basal State

Under normal (non-stressed) conditions:

Nrf2 binds to the Kelch domain of KEAP1 as a dimeric complex

The KEAP1-Cullin3-RBX1 E3 ubiquitin ligase complex ubiquitinates Nrf2

Ubiquitinated Nrf2 is targeted for proteasomal degradation

This maintains low basal levels of Nrf2 in the cytoplasm

Mermaid diagram (expand to render)

Oxidative Stress Response

Upon oxidative or electrophilic stress:

Reactive oxygen species (ROS) or electrophiles modify critical cysteine residues on KEAP1

This induces a conformational change that blocks Cullin3-mediated ubiquitination

Stabilized Nrf2 escapes degradation and translocates to the nucleus

In the nucleus, Nrf2 heterodimerizes with [small Maf proteins](/proteins/maf-protein)

The Nrf2-Maf complex binds to Antioxidant Response Elements (ARE) in DNA

This activates transcription of ~200-300 target genes involved in:

Glutathione synthesis and metabolism
Drug detoxification (phase I and II enzymes)
Iron metabolism (ferritin)
NADPH generation
Proteasome and autophagy components
Heme oxygenase-1 (HO-1)

Key Target Genes

Negative Feedback Regulation

The pathway is tightly regulated through several feedback mechanisms:

KEAP1 induction: Nrf2 activation leads to increased KEAP1 expression, restoring basal repression

Nrf2 degradation signals: Phosphorylation of Nrf2 by GSK3β creates new degron sites

Autophagic clearance: p62-mediated autophagy can degrade KEAP1 itself

CRL3 complex turnover: New Cullin 3 synthesis helps restore ubiquitination capacity

Regulation of KEAP1 Expression

Transcriptional Regulation

KEAP1 expression is itself regulated by multiple mechanisms:

Nrf2-dependent regulation: Nrf2 can activate KEAP1 transcription, creating a negative feedback loop [1]

Hypoxia-inducible factors (HIF): Under hypoxic conditions, HIF-1α can induce KEAP1 expression [2]

p53: The tumor suppressor p53 can suppress KEAP1 expression under certain conditions [3]

MicroRNAs: miR-200 family members target KEAP1 mRNA, particularly in epithelial-mesenchymal transition [4]

Post-Translational Modifications

Beyond cysteine oxidation, KEAP1 undergoes various modifications:

Phosphorylation: Casein kinase 2 (CK2) phosphorylates KEAP1, enhancing its ability to sequester Nrf2

Ubiquitination: KEAP1 itself can be ubiquitinated and degraded under certain stress conditions

Sumoylation: SUMO modification of KEAP1 affects its subcellular localization and function

Acetylation: Acetylation of KEAP1 regulates its interaction with Nrf2

Subcellular Localization

KEAP1 is primarily localized in the cytoplasm, where it forms a complex with Nrf2. However, under certain conditions:

A portion of KEAP1 localizes to the nucleus, where it can sequester nuclear Nrf2
Oxidative stress can alter KEAP1 distribution
Post-translational modifications affect its trafficking

KEAP1 in Neurodegenerative Diseases

Alzheimer's Disease

In [Alzheimer's disease](/diseases/alzheimers-disease), the KEAP1-Nrf2 pathway shows complex alterations:

Impaired Nrf2 Activation: Despite elevated oxidative stress markers in AD brains, Nrf2 nuclear translocation and ARE activation are attenuated. This suggests a "functional" KEAP1-Nrf2 pathway impairment [5].

Amyloid-β Interaction: Amyloid-beta (Aβ) peptides can directly oxidize cysteine residues on KEAP1, leading to dysregulated Nrf2 activation. Some studies show reduced KEAP1 levels in AD brains, potentially due to oxidative modification.

Glial Cell Dysfunction: In astrocytes and microglia surrounding amyloid plaques, Nrf2 activation is blunted. This reduces the capacity of glial cells to handle oxidative stress generated by Aβ accumulation.

Therapeutic Implications:

Nrf2 activators (e.g., sulforaphane, bardoxolone methyl) show promise in preclinical AD models
The concept of "Nrf2 activators" as disease-modifying AD therapeutics is under investigation
Clinical trials (e.g., the SAK3 study and others) are evaluating Nrf2-targeted approaches

Tau Pathology Connection: Hyperphosphorylated tau protein interacts with KEAP1, potentially disrupting Nrf2 signaling. Studies show that tau pathology correlates with reduced Nrf2 nuclear localization in AD brains.

Mitochondrial Dysfunction: The KEAP1-Nrf2 pathway intersects with mitochondrial quality control. In AD, mitochondrial dysfunction leads to increased ROS production, which should theoretically activate Nrf2. However, this adaptive response appears impaired.

Cognitive Decline Correlation: Studies have shown that Nrf2 activity inversely correlates with cognitive decline in AD patients. Higher Nrf2 nuclear localization is associated with better cognitive outcomes.

Parkinson's Disease

The KEAP1-Nrf2 pathway is particularly relevant to [Parkinson's disease](/diseases/parkinsons-disease) due to the profound oxidative stress in dopaminergic neurons:

Inherent Vulnerability: Dopaminergic neurons in the substantia nigra pars compacta (SNc) have inherently low Nrf2 activity, making them dependent on KEAP1-Nrf2 signaling for redox homeostasis [6].

Genetic Associations: Polymorphisms in KEAP1 have been associated with sporadic PD risk in some populations. Additionally, mutations in genes encoding proteins degraded by the ubiquitin-proteasome system (like [parkin](/genes/parkin) and [PINK1](/genes/pink1)) can lead to increased oxidative stress.

Environmental Toxins: PD-inducing toxins like MPTP and 6-OHDA activate Nrf2 as a compensatory response. However, this response is insufficient to prevent neuronal death.

Alpha-Synuclein Interaction: Alpha-synuclein ([SNCA](/genes/snca)) aggregation can sequester Nrf2 in the cytoplasm, preventing its nuclear translocation and transcriptional activity.

Therapeutic Targeting:

Nrf2 activators protect dopaminergic neurons in multiple PD models
The compound dimethyl fumarate (Tecfidera) has been tested in PD clinical trials
Gene therapy approaches to enhance Nrf2 are under investigation

Dopamine Metabolism: The oxidation of dopamine itself generates reactive species, creating chronic oxidative stress in dopaminergic neurons that makes them particularly dependent on Nrf2-mediated protection.

LRRK2 Connection: Mutations in [LRRK2](/genes/lrrk2), a common genetic cause of PD, are associated with dysregulated Nrf2 signaling. LRRK2 can interact with KEAP1-Nrf2 pathway components.

Amyotrophic Lateral Sclerosis (ALS)

Motor Neuron Vulnerability: Motor neurons exhibit relatively low basal Nrf2 activity, similar to dopaminergic neurons

KEAP1 Mutations: Rare KEAP1 mutations have been identified in familial ALS cases

Oxidative Stress: ALS motor neurons face elevated oxidative stress from mitochondrial dysfunction and glutamate excitotoxicity

Therapeutic Potential: Nrf2 activators have shown protective effects in SOD1 mouse models of ALS

Huntington's Disease

Transcriptional Dysregulation: Mutant huntingtin protein impairs Nrf2 nuclear translocation

Oxidative Stress: Elevated ROS and RNS in HD brains

Therapeutic Benefits: Nrf2 activation improves motor performance and reduces striatal degeneration in HD mouse models

Multiple Sclerosis

Neuroinflammation: Nrf2 activation reduces pro-inflammatory cytokine production in microglia

Demyelination: Antioxidant protection promotes oligodendrocyte survival

Clinical Use: Dimethyl fumarate (Tecfidera) is an approved MS treatment that works partly through Nrf2 activation

Other Neurodegenerative Conditions

Therapeutic Targeting of KEAP1

Direct Nrf2 Activators (KEAP1 Inhibitors)

These compounds covalently modify cysteine residues on KEAP1:

Sulforaphane: Naturally occurring isothiocyanate from broccoli sprouts; activates Nrf2 by modifying C151
Bardoxolone methyl (CDDO-Me): Synthetic triterpenoid; strong Nrf2 activator
Dimethyl fumarate (DMF): Approved for MS treatment; activates Nrf2
Equol (S-equol): Soy-derived isoflavone with Nrf2-activating properties
Curcumin: Polyphenol from turmeric; activates Nrf2 through multiple mechanisms
Epigallocatechin-3-gallate (EGCG): Green tea catechin with Nrf2-activating properties

Indirect Nrf2 Activators

These compounds activate Nrf2 through KEAP1-independent mechanisms:

Protor: Nrf2 stabilizer via p62 phosphorylation
Oltipraz: Dithiolethione compound
Aspirin: Can activate Nrf2 through inhibition of IKKβ

Pharmacological Considerations

Cysteine Selectivity: Different activators show preferences for different cysteine residues

Reversibility: Some modifiers form reversible adducts while others are irreversible

Bioavailability: CNS penetration varies significantly among compounds

Dosing Effects: Acute vs. chronic dosing can produce different outcomes

Clinical Trials in Neurodegeneration

Challenges in CNS Drug Delivery

Blood-Brain Barrier: Many Nrf2 activators have poor CNS penetration

Paradoxical Effects: Constitutive Nrf2 activation can be deleterious due to altered cellular metabolism

Specificity: Some electrophiles modify proteins beyond KEAP1

Dosing: Optimal dosing regimens for neuroprotection remain unclear

Interaction Network

KEAP1 interacts with multiple proteins beyond Nrf2:

CUL3: Scaffold for ubiquitin ligase complex
RBX1: RING-box protein, E3 ubiquitin ligase component
p62/SQSTM1: Autophagy receptor that competes with Nrf2 for KEAP1 binding; phosphorylation of p62 enhances Nrf2 activation
IKKβ: Can phosphorylate Nrf2, disrupting KEAP1 binding
PGAM5: Mitochondrial phosphatase that influences KEAP1-Nrf2 signaling
AMPK: Energy sensor that can activate Nrf2
PKC: Can phosphorylate Nrf2, promoting its release from KEAP1
GSK3β: Phosphorylates Nrf2, facilitating its degradation

Mermaid diagram (expand to render)

Autophagy-KEAP1-Nrf2 Connection

The intersection between autophagy and the KEAP1-Nrf2 pathway represents a critical regulatory node:

p62-Mediated Activation: The autophagy receptor p62/SQSTM1 can compete with Nrf2 for KEAP1 binding. When p62 is phosphorylated at S403, it has higher affinity for KEAP1, leading to Nrf2 activation.

Selective Autophagy: KEAP1 itself can be degraded through selective autophagy, providing another mechanism for Nrf2 activation.

Aggrephagy: The clearance of protein aggregates involves both Nrf2 activation and autophagy, which may be therapeutically relevant for neurodegenerative diseases.

Mitophagy: The selective autophagy of damaged mitochondria intersects with Nrf2 signaling, particularly relevant to PD.

Therapeutic Implications: Compounds that enhance autophagy (like rapamycin) can potentiate Nrf2 activation through this mechanism.

Genetic Aspects of KEAP1

Polymorphisms

Several KEAP1 polymorphisms have been associated with disease susceptibility:

rs4135450: Associated with increased PD risk in some populations
rs1048290: May influence cancer risk but also relevant to neurodegeneration
rs5754449: Polymorphism in the promoter region affecting expression
rs11076161: Associated with altered KEAP1 expression levels

Somatic Mutations

Somatic KEAP1 mutations are frequently found in lung cancer and other tumors. These mutations typically disrupt the KEAP1-Nrf2 pathway, conferring a growth advantage to cancer cells.

Epigenetic Regulation

KEAP1 expression is also regulated by epigenetic mechanisms:

Promoter methylation can silence KEAP1 expression in certain cancers
Histone modifications affect KEAP1 transcription
Non-coding RNAs regulate KEAP1 mRNA stability

Animal Models

Knockout Studies

Keap1 knockout mice: Embryonic lethal due to severe oxidative stress
Liver-specific Keap1 knockout: Viable with enhanced Nrf2 activity and resistance to hepatotoxins
Brain-specific Keap1 knockout: Viable with elevated Nrf2 in neural tissues

Transgenic Models

Nrf2 knockout mice: More susceptible to neurodegenerative models
Keap1 conditional knockout: Used to study Nrf2 activation in specific tissues
Humanized KEAP1 mice: Model for testing human-specific KEAP1 interactions

Disease Models

6-OHDA PD model: Nrf2 activation protects dopaminergic neurons
MPTP model: Similar neuroprotective effects observed
Amyloid-beta AD model: Nrf2 activators reduce plaque load and improve cognition
SOD1 ALS model: Nrf2 activation delays disease onset

Biomarkers of KEAP1-Nrf2 Pathway Activity

Direct Biomarkers

Nrf2 nuclear localization: Measured by immunohistochemistry or Western blot

Target gene expression: NQO1, HO-1, GCLC mRNA levels

KEAP1 oxidation status: Detection of oxidized cysteine residues

Indirect Biomarkers

Glutathione levels: Peripheral blood GSH as a proxy for antioxidant capacity

Oxidative stress markers: 8-OHdG, lipid peroxidation products

Inflammatory cytokines: IL-6, TNF-α as indicators of neuroinflammation

Cross-Linking to Other Neurodegeneration Pathways

The KEAP1-Nrf2 pathway intersects with multiple other neurodegeneration-related mechanisms:

Mitochondrial Dynamics: Nrf2 activation promotes mitochondrial biogenesis through PGC-1α expression

Neuroinflammation: Nrf2 suppresses pro-inflammatory gene expression in microglia

Protein Aggregation: Autophagy induction through p62 helps clear aggregate-prone proteins

DNA Repair: Nrf2 enhances expression of DNA repair enzymes

Iron Metabolism: Ferritin upregulation protects against iron-induced oxidative damage

Connections to Specific Neurodegeneration Proteins

Comparative Biology

Evolutionary Conservation

The KEAP1-Nrf2 pathway is highly conserved across eukaryotes:

Drosophila: The KEAP1 ortholog is called "Cnc" (cap'n'collar), paired with the Nrf2 ortholog "SKn-1"
Zebrafish: Both KEAP1 and Nrf2 are well conserved, used as model for developmental studies
Rodents: High homology to human proteins, with similar domain structure
Primates: Near-identical protein sequences across great apes

Species-Specific Differences

Human KEAP1 has additional regulatory features not present in rodents
Some Nrf2 target genes differ between species
The cysteine sensor positions are highly conserved

Future Directions

Emerging Therapeutic Strategies

Gene therapy: AAV-mediated Nrf2 delivery to the CNS

Nrf2 stabilizers: Small molecules that prevent Nrf2 degradation without modifying KEAP1

Combination therapies: Nrf2 activators with other neuroprotective agents

Personalized approaches: KEAP1/Nrf2 genotype-informed treatment

Unresolved Questions

Why does the pathway become unresponsive in chronic neurodegenerative conditions?

What is the optimal balance between Nrf2 activation and cellular homeostasis?

How do different cell types (neurons vs. glia) utilize this pathway differently?

Can we develop Nrf2 activators with improved CNS penetration?

What is the role of KEAP1-independent Nrf2 activation in neurodegeneration?

Summary

KEAP1 is a critical oxidative stress sensor that controls the Nrf2 transcriptional program. In neurodegenerative diseases, dysfunction of this pathway contributes to the failure of cellular antioxidant defenses. The pathway intersects with multiple cellular processes including autophagy, mitochondrial quality control, and neuroinflammation. Therapeutic modulation of the KEAP1-Nrf2 pathway remains an active area of research with potential for disease-modifying treatments in AD, PD, and related conditions.

External Links

[GeneCards: KEAP1](https://www.genecards.org/cgi-bin/carddisp.pl?gene=KEAP1)

References

[Kensler et al., Cell survival pathways and the transcription factor Nrf2 (2007) (2007)](https://doi.org/10.1016/j.ceb.2007.06.005)

[Zhang et al., The role of Nrf2/KEAP1 signaling pathway in Alzheimer's disease (2020) (2020)](https://doi.org/10.1016/j.neurobiolaging.2020.04.010)

[Ramsey et al., Copy number and expression analysis of Nrf2 and its negative regulator KEAP1 in Parkinson's disease brains (2007) (2007)](https://pubmed.ncbi.nlm.nih.gov/17295056/)

[Inoue et al., Nrf2/KEAP1 pathway and neurodegeneration (2019) (2019)](https://doi.org/10.1007/s11064-019-02769-4)

[Cuadrado et al., Nrf2 as a therapeutic target in neurodegenerative diseases (2019) (2019)](https://doi.org/10.1016/j.tips.2019.07.002)

[Sundaram et al., Targeting the KEAP1-NRF2 pathway for neurodegenerative disease treatment (2024) (2024)](https://doi.org/10.1016/j.pharmther.2024.108652)

[Dinkova-Kostova et al., KEAP1, the sensory subunit of the Cullen3-based ubiquitin ligase complex (2015) (2015)](https://doi.org/10.1016/j.jmb.2015.09.016)

[Unknown, Talalay, The importance of using science in the development of Nrf2 activators (2019) (2019)](https://doi.org/10.1016/j.freeradbiomed.2019.10.002)

📖 View canonical wiki page →

Related Entities

KEAP1PROTEIN

▸Metadataorigin_type: v1_polymorphic_backfill

slug	proteins-keap1-protein
kg_node_id	KEAP1PROTEIN
entity_type	protein
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-b96836526c78
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'proteins-keap1-protein'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

95%

Debates

0

Incoming

19

Outgoing

25

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

KEAP1 Protein

KEAP1 Protein

KEAP1 Protein

Introduction

Structure and Biochemistry

Domain Architecture

Cysteine Sensors

Three-Dimensional Structure

Protein-Protein Interactions

The KEAP1-Nrf2 Signaling Pathway

Basal State

Oxidative Stress Response

Key Target Genes

Negative Feedback Regulation

Regulation of KEAP1 Expression

Transcriptional Regulation

Post-Translational Modifications

Subcellular Localization

KEAP1 in Neurodegenerative Diseases

Alzheimer's Disease

Parkinson's Disease

Amyotrophic Lateral Sclerosis (ALS)

Huntington's Disease

Multiple Sclerosis

Other Neurodegenerative Conditions

Therapeutic Targeting of KEAP1

Direct Nrf2 Activators (KEAP1 Inhibitors)

Indirect Nrf2 Activators

Pharmacological Considerations

Clinical Trials in Neurodegeneration

Challenges in CNS Drug Delivery

Interaction Network

Autophagy-KEAP1-Nrf2 Connection

Genetic Aspects of KEAP1

Polymorphisms

Somatic Mutations

Epigenetic Regulation

Animal Models

Knockout Studies

Transgenic Models

Disease Models

Biomarkers of KEAP1-Nrf2 Pathway Activity

Direct Biomarkers

Indirect Biomarkers

Cross-Linking to Other Neurodegeneration Pathways

Connections to Specific Neurodegeneration Proteins

Comparative Biology

Evolutionary Conservation

Species-Specific Differences

Future Directions

Emerging Therapeutic Strategies

Unresolved Questions

Summary

See Also

External Links

References

💬 Discussion